who owns semaglutide patent Brazilian federal court denies extension Novo Nordisk Takes Telehealth Company

The STEP trials, which enrolled thousands of patients for weight management, did not identify sexual dysfunction as a notable adverse effect

The data shows that discontinuing GLP-1 medications leads to significant weight regain in the majority of patients

Do not freeze your semaglutide pens under any circumstances

In clinical trials, semaglutide at the 2.4 mg weekly dose produced average weight loss of approximately 15% of body weight over 68 weeks

In a recent study of 28,315 patients with incident T2D, around half of patients spent the 10 years after diagnosis with HbA 1c above desired targets: mean percent time spent with HbA 1c 7% was 40% in the first 2 years and 61% after 610 years (3)